Industrias
Life Science Tools
Todos los análisis de Life Science Tools — 14 análisis.
48/100
Danaher: Orders and Peers Make the Bioprocessing Recovery Underwritable, but 3-4% Core Growth at 23 Times Earnings Leaves No Margin of Safety
Danaher sells recurring bioprocessing, laboratory and diagnostic workflows through specialised operating companies run on the Danaher Business System, with Cytiva consumables, Cepheid cartridges and Beckman reagents supplying most of the profit pool. Second-quarter core growth was 3.0% while more than 100 million USD of chromatography-resin shipments moved into 2027, and goodwill and intangibles reached 74.5% of assets after the 9.8 billion USD Masimo purchase, against acquisition-inclusive ROIC near 6 to 7%. Rating Hold: peer consumables data make the bioprocessing recovery underwritable, but at 23.4 times guided adjusted EPS the price already pays for a conversion Danaher cannot schedule.
42/100
49Buffett
QIAGEN: Sticky Workflow Economics With Takeover Optionality Already in the Price
QIAGEN is a molecular diagnostics and life-science tools company that monetizes an entire lab workflow, from sample prep to assays, automation and bioinformatics, selling to more than 500,000 customers across five growth pillars that target about $1.61 billion of 2026 sales. The recurring consumables model is genuinely sticky, but core organic growth still needs repair while the stock carries takeover optionality after Reuters reported KKR and strategic interest. Rating Hold: at $41.51 the shares sit inside the acceptable-hold band of $39-53, above the ideal buy zone of $30-32, so buyers are paying for both a standalone repair and a deal premium that may not arrive.
45/100
Bio-Rad Laboratories: A Company in Transition, Priced Without a Margin of Safety
Bio-Rad is a diversified life-science tools and clinical-diagnostics supplier whose core operations generated 2.58 billion USD of 2025 sales, complicated by an unusually large Sartorius AG stake that dominates its GAAP earnings. Q1 2026 brought a 527.1 million USD net loss driven by a 727.7 million USD fair-value drop on the Sartorius stake, even as the operating business still produced 108.1 million USD of operating cash flow, and management cut full-year currency-neutral revenue guidance to a range of -3.0% to +0.5%. Rating Hold: durable niche assets and real asset backing, but at 297.09 USD the price already assumes the 2026 slowdown is manageable and leaves no margin of safety.
49/100
Merck KGaA: una plataforma científica diversificada en transición
Merck KGaA, Darmstadt, es un grupo alemán de ciencia y tecnología controlado por una familia, con €21.1 mil millones de ventas en 2025 procedentes de tres motores muy distintos: un negocio de Healthcare expuesto a patentes, una franquicia de herramientas de Life Science de alta calidad y un negocio de Electronics de materiales para semiconductores. La acción en 2026 vive un tira y afloja: el conocido vencimiento de la patente estadounidense de Mavenclad pesa sobre Healthcare, mientras Process Solutions crece cerca de 10% orgánico y Electronics se beneficia de la demanda de IA en nodos avanzados, dejando la acción cerca de 15.9 veces el EPS pre de 2025 y con una rentabilidad de flujo de caja libre de 3.5% tras el rebote de mayo hasta €133.05. Calificación Mantener: los motores realmente sólidos de Life Science y materiales para semiconductores compensan un Healthcare con credibilidad dañada, pero el descuento permanente de gobierno KGaA y una valoración solo razonable limitan el potencial alcista.
51/100
Sartorius AG: una recuperación de bioprocesamiento de calidad que ya está en el precio
Sartorius AG es un grupo alemán de herramientas para ciencias de la vida cuyo valor depende sobre todo de su franquicia de bioprocesamiento, Sartorius Stedim Biotech, controlada por mayoría, mientras que la cotización líquida es la acción preferente sin voto SRT3. Tras el auge pandémico y el ajuste de inventarios, las ventas de 2025 se recuperaron 7.6% hasta unos EUR 3.54 mil millones, el margen EBITDA subyacente volvió a 29.7% y el apalancamiento bajó de 3.96x a 3.55x, aunque cerca de EUR 3.74 mil millones de deuda neta y un múltiplo todavía exigente de 18x EBITDA trailing dejan poco margen. Calificación Mantener: la franquicia y la recuperación son reales, pero el mercado ya descuenta la normalización y el precio actual de EUR 217.10 está por encima de la zona ideal de compra del informe.
42/100
Investigación en profundidad de 10x Genomics
10x Genomics es una compañía de plataformas de ómica unicelular y espacial cuyos instrumentos instalados impulsan compras recurrentes de consumibles de alto margen; estos consumibles han representado durante mucho tiempo cerca del 84% al 86% de los ingresos. A medida que se ralentiza el crecimiento de Chromium, el siguiente relevo de crecimiento depende de Atera, lanzado en abril de 2026, pero la empresa sigue generando pérdidas y alrededor del 40% al 50% de los ingresos depende de financiación académica y gubernamental. Calificación de investigación Mantener: al precio actual de USD 28.84, la acción cotiza a cerca de 5.1x EV/Ventas futuras, un nivel razonable pero sin margen de seguridad.
41/100
Bruker Zen Horizon Research: A Hidden Champion in Scientific Instruments, but Organic Growth Is Receding and Valuation Has Priced In the Recovery
Bruker is a hidden global champion in high-end scientific analytical instruments, with a near-oligopoly position in NMR. Organic growth has turned negative for consecutive periods, reported growth is being held up by acquisitions and FX, GAAP earnings have swung to a loss, and the profit recovery depends heavily on cost execution after a roughly 70% one-month surge left the current price of $59.97 above the average sell-side target by 16% and forward PE at about 27-28x near the top of peers. Research rating Watch: a high-quality moat business that needs either a confirmed organic inflection or a pullback toward roughly $48 to restore margin of safety.
27/100
Bio-Techne Corporation: A Deep Value Investing Study
A high-quality life-science tools company trading at a rich price. At $51.68 the stock carries a trailing P/E of roughly 74.9x while three-year revenue has compounded at only 3.3%, so the margin of safety is thin. Rating Watch: ideal entry sits at $28-35, with the roughly $1 billion Wilson Wolf follow-on acquisition as the key risk to monitor.
43/100
Revvity In-Depth Value Investment Research
Revvity is a life sciences and diagnostics tools company with understandable businesses and acceptable cash generation. The core thesis is that its recurring revenue mix and focused portfolio are attractive, but its moat and capital returns are not strong enough to offset low-single-digit GAAP ROIC, $6.6 billion of goodwill, and a share price already near the low end of the optimistic case. Research rating Watch: a quality business with insufficient margin of safety at the current price, with a fair buy range of $50 to $65.
45/100
90Buffett
Mettler-Toledo International Inc.: A Value Investing Deep Dive
A global leader in precision instruments and services with excellent quality, but at roughly $1,161 the stock trades at about 27x P/E and about 28x conservative owner earnings, already close to the optimistic scenario, so the rating is Watch; the ideal buy range is $800-950; the main risks are competition in China and emerging markets, tariff erosion of gross margin, and buybacks at high valuations.
46/100
Long-Term Research on Waters' Laboratory Analytics and Diagnostic Tools
Waters sells liquid chromatography, mass spectrometry, thermal analysis, software, consumables, and services, and after acquiring BD Biosciences it has become a life-sciences and diagnostics platform. At $342, the stock is already close to the optimistic valuation band, while the ideal buy range is $200-240. Rating Watch: a high-quality business, but current pricing leaves too little margin of safety before integration and cash-flow proof improve.
48/100
Danaher Research from a Long-Term Owner's Perspective
Danaher is a platform spanning bioprocessing, life sciences, and diagnostics, with 2025 revenue of $24.668 billion, free cash flow of roughly $5.29 billion, and recurring revenue at 82%. At the current share price of $172, the stock trades at about 23x FCF, which places it in a fair-value band without enough margin of safety. Rating Watch: a durable compounder worth studying and holding, but better approached after a wider discount emerges.
47/100
69Buffett
Thermo Fisher: A Long-Term Owner's Perspective
Thermo Fisher Scientific is a full-stack scientific infrastructure platform spanning instruments, consumables, services, CRO, and CDMO capabilities. At $448, with a static P/E of 24.6x and $65.2 billion of goodwill and acquisition-related intangibles, long-term returns depend heavily on acquisition quality and execution. Rating Watch: a high-quality business, but the current price does not offer a clearly sufficient margin of safety.
44/100
83Buffett
Agilent Technologies: A Study from a Long-Term Business Owner's Perspective
A high-quality laboratory tools and services company whose CrossLab services/consumables franchise is highly sticky, with solid cash flow and low debt. At the current $113.78, mid-single-digit growth is already fully priced in and the margin of safety is insufficient; rating Watch, with an ideal buy zone of $70-85.